Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

Authors
Category Primary study
Registry of TrialsJapan Primary Registry Network
Year 2024
This article has no abstract
Epistemonikos ID: cdf50c011b019b5eae1ae955ad01a09a6dd298df
First added on: Apr 11, 2025